Early loss of serum hepatitis C virus RNA can predict a sustained response to interferon therapy in patients with chronic hepatitis C

American Journal of Gastroenterology

Volumn 92, Issue 1, 1997, Pages 61-65

  Karino, Yoshiyasu ^a   Toyota, Jouji ^b   Sugawara, Masaaki ^b   Higashino, Kiyoshi ^b   Sato, Takahiro ^b   Ohmura, Takumi ^b   Suga, Toshihiro ^b   Okuuchi, Yutaka ^b   Matsushima, Takashi ^b  

^a Sapporo Kosei General Hospital   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS C ANTIBODY; VIRUS RNA;

ADULT; AGED; ARTICLE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHRONIC DISEASE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RNA, VIRAL; TIME FACTORS;

EID: 0031021643     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human interferon. A preliminary report. N Engl J Med 1986;315:1575-8.
2. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: A multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
3. DiBisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989;321:1506-10.
4. Iino S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high-dose interferon alpha-2b: A multicenter study. Dig Dis Sci 1993; 38:612-8.
5. Pagliaro L, Craxi A, Cammaa C, et al. Interferon-alpha for chronic hepatitis C: An analysis of pretreatment clinical predictors of response. Hepatology 1994;19:820-8.
6. Martinot-Peignoux M, Marcellin P, Pouteau P, et al. Pretreatment serum hepatitis C virus levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alpha therapy in chronic hepatitis C. Hepatology 1995;22: 1050-6.
7. Okada S, Akahane Y, Suzuki H, et al. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients. Hepatology 1992;16:619-24.
8. Wolfe L, Tamatsukuri S, Sayada C, et al. Detection of HCV RNA in serum using a single-tube, single enzyme PCR in combination with a colorimetric microwell assay. Hepatitis C Virus. GEMHEP. Paris: John Libbey Eurotext, 1994, 83-84.
9. Karen Y, Jennifer A, Yokosuka O, et al. Detection of hepatitis C virus RNA by a combined reverse transcription PCR assay: Comparison with nested amplification and antibody testing. J Clin Microbiol 1995; 33:654-7.
10. Okamoto H, Okada S, Sugiyama Y, et al. The 5′-terminal sequence of the hepatitis C virus genome. Jpn J Exp Med 1990;60:167-77.
11. Usui M, Yamaguchi M, Sugimura Y, et al. Evaluation of SepaGene RV for type C chronic hepatitis virus on speedy separation and purifying. Igaku to Yakugaku 1994;32:99-103.
12. Tamatsukuri S, Shiratori Y, Kato N, et al. Monitoring of HCV-RNA during and after IFN-therapy by using a single-tube, single enzyme RT-PCR. Kan-tan-sui 1995;30:921-5.
13. Karen Y, Robert R, Thomas M. Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993;31:882-6.
14. Davis G, Lau JY, Urdeaa MS, et al. Quantitative detection of hepatitis C virus RNA with a solid-phase signal amplification methods: Detection of the optimal conditions for specimen collection and clinical application in interferon-treated patients. Hepatology 1994;19:1337-41.
15. Okamoto H, Sugiyama Y, Okada S, et al. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol 1992;73: 673-9.
16. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19: 1321-4.
17. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different dose of interferon-alpha 2b. Hepatology 1993;18:1300-5.
18. Shindo M, Di-Bisceglie AM, Hoofnagle JH. Long-term follow-up of patients with chronic hepatitis C treated with alpha-interferon. Hepatology 1992;15:1013-6.
19. Yamada G, Takatani M, Kishi F, et al. Efficacy of interferon alpha therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level. Hepatology 1995;22:1351-4.
20. Orito E, Mizokami M, Suzuki K, et al. Loss of serum HCV RNA at week 4 of interferon-alpha therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995;46:109-15.
21. Hino K, Okuda M, Konishi T, et al. Serial assay of hepatitis C virus RNA in serum for predicting response to interferon-alpha therapy. Dig Dis Sci 1995;40:14-20.